Home > Insider Trading > Filing (0001179110-19-010682)

Filing Details

Accession Number:: 0001179110-19-010682
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-09-26 18:22:44
Reporting Period:: 2019-09-25

Accepted Time:: 2019-09-26 18:22:44
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1130598	Onconova Therapeutics Inc.	ONTX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1198578	J James Marino	C/O Onconova Therapeutics 375 Pheasant Run Newtown PA 18940		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-09-25	7,260	$1.60	16,942	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Series A Convertible Preferred Stock	Warrant (right to purchase)	Disposition	2019-09-25	5,000	$0.00	5,000	$1.01
Series A Convertible Preferred Stock	Warrant (right to purchase)	Acquisiton	2019-09-25	5,000	$0.00	5,000	$0.11
Series B Convertible Preferred Stock	Warrant (right to purchase)	Disposition	2019-09-25	1,473	$0.00	1,473	$0.43
Series B Convertible Preferred Stock	Warrant (right to purchase)	Acquisiton	2019-09-25	1,473	$0.00	1,473	$0.11

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2018-02-12		No	4	H	Direct
5,000	2019-09-25	2022-12-31	No	4	P	Direct
0	2018-05-01		No	4	H	Direct
1,473	2019-09-25	2022-12-31	No	4	P	Direct

Footnotes

These warrants were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $1.01.
The warrants were exercisable immediately at an exercise price of $1.01 per 0.1 share of Series A Convertible Preferred Stock and would expire on the later of (i) the one-year anniversary of the date on which theCompany publicly announces through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware and (ii) the earlier of (A) the one-month anniversary of the date on which the Company publically releases certain topline results of the INSPIRE Pivotal phase 3 trial that compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk and (B) December 31, 2019.
In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series A preferred stock, previously purchased on February 12, 2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $1.01 per 0.1 share of Series A Preferred Stock to $0.10667 per 0.1 share of Series A Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series A Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock).
These warrants were acquired in a public offering, by the Company, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425.
The warrants were exercisable immediately at an exercise price of $0.425 per 0.025 share of Series B Convertible Preferred Stock and would expire on the 18-month anniversary of the date on which the Company publicly announced through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware.
In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series B preferred stock, previously purchased on May 1,2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $0.425 per 0.025 share of Series B Preferred Stock to $0.10667 per 0.025 share of Series B Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series B Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock).